Corbus Pharmaceuticals Set to Unveil CRB-913 Obesity Trial Data
Event summary
- Corbus Pharmaceuticals will host a conference call on September 14, 2026, to discuss topline data from the CANYON-1 Phase 1b trial of CRB-913 for obesity treatment.
- The trial is a 16-week, double-blind, placebo-controlled study involving 240 obese, non-diabetic adult participants across multiple U.S. clinical sites.
- CRB-913 is a once-daily, highly peripherally restricted oral CB1 inverse agonist, offering an alternative to GLP-1 and other incretin-targeting therapies.
- Harold Bays, M.D., a prominent obesity researcher, will join the conference call as a guest speaker.
The big picture
Corbus Pharmaceuticals is positioning CRB-913 as a potential game-changer in obesity treatment, targeting a market increasingly dominated by GLP-1 agonists. The CANYON-1 trial results could validate the company's approach of using a CB1 inverse agonist, offering an alternative mechanism for weight loss and long-term management. The involvement of Harold Bays, a leading obesity researcher, underscores the strategic importance of this data release.
What we're watching
- Clinical Efficacy
- How the topline data from the CANYON-1 trial will position CRB-913 against existing obesity treatments, particularly GLP-1 agonists.
- Regulatory Pathway
- The pace at which Corbus can advance CRB-913 through subsequent clinical phases and potential regulatory approvals.
- Market Differentiation
- Whether CRB-913's peripheral restriction and once-daily dosing can offer a sustainable competitive advantage in the obesity market.